The addition of low‐dose‐rate brachytherapy and androgen‐deprivation therapy decreases biochemical failure and prostate cancer death compared with dose‐escalated external‐beam radiation therapy for high‐risk prostate cancer
1. Department of Radiation Oncology, University of Michigan Health System, Ann Arbor, Michigan;2. Department of Radiation Oncology, Cedars‐Sinai Medical Center, Los Angeles, California